Dominik Hartl

Dominik Hartl serves as the Chief Medical Officer at Granite Bio, focusing on the development of therapeutic antibodies since October 2022. Concurrently, Hartl is a Professor of Pediatric Immunology at the Hospital of the University of Tübingen, engaging in translational research and clinical studies related to immune-mediated diseases and publishing extensively in areas such as immunology and tissue inflammation since July 2010. Additionally, a part-time Professor at the University of St.Gallen as of January 2025, Hartl contributes to the Competence Center for Pharma Innovation. Previous roles include Chief Medical Officer positions at Vector BioPharma and Quell Therapeutics, where efforts were directed towards gene delivery biotechnologies and CAR-Treg cell therapies for autoimmune and metabolic diseases, respectively. Educational credentials include a Post-Doc in Immunology from Yale School of Medicine and an MBA program undertaken at Boston University.